← Home / REGENERON PHARMACEUTICALS, INC. (REGN)
Stock Analysis

REGENERON PHARMACEUTICALS, INC. (REGN)

REGN
REGN · Healthcare • Biotechnology
840.80 -1.32%
Track REGN in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when REGN price is:
52W Range Position
96%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-09-03 19:43 UTC
WOI Investment Thesis
Constructive
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Strong / Strong / Healthy / Strong
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
Primary setup trigger already cleared; this level remains the breakout reference.
842.65
🎯
Next Objective
Primary pattern objective while the setup remains active.
968.69
×
Thesis Break
Primary technical setup invalidates below this level.
Below 779.20
Recent Company Events
SEC VERIFIED
Latest material filings
JUL
30
●
Financial Results
HIGH
REGN reports financial results
(Exact name of registrant as specified in its charter) New York 000-19034 13-3444607 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S.
8-K Filing • SEC EDGAR
JUL
6
●
Financial Results
HIGH
REGN reports financial results
(“ Regeneron ” or the “ Company ”) currently expects that its financial results calculated in accordance with U.S.
8-K Filing • SEC EDGAR
APR
29
●
Financial Results
HIGH
Regeneron Reports First Quarter 2026 Financial and Operating Results
• First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025 • Dupixent ® global net sales (recorded by Sanofi) increased 33% to $4.9 billion • EYLEA HD ® U.S.
8-K Filing • SEC EDGAR
What's Driving REGN?
✓ Technical setup is active
Momentum is Neutral. Primary trigger is Above 842.65 with structure risk at Below 779.20.
✓ Business quality is supportive
Revenue growth is strong. Profitability is strong. Cash generation is healthy. Balance-sheet quality is strong.
⚠️ Key risk remains
Below 779.20
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
A confirmed technical structure is active. Use its trigger, target and invalidation levels for context.
Pattern
Bull Flag · Confirmed
Trigger
842.65
Target
968.69
Invalidation
779.20
Bull Flag
Q 0.88 / age 1
Flag Target
968.69
Price Chart
REGN — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-09-02
Fair
Fair valuation
The earnings multiple is in a moderate range.
Market Cap
$84.8B
Company size
EV
$77.0B
Debt-adjusted value
P/E
20.4
Reasonable
P/S
5.5
Balanced
P/B
2.6
Balanced
EV/Sales
5.0
Balanced
EV/EBIT
15.0
Low multiple
P/FCF
27.7
Reasonable
FCF Yield
3.61%
Cash return
Not financial advice
Business Lens
Improving financial execution
Growth, profitability, cash flow and balance sheet quality remain broadly supportive.
↗
Revenue Growth
Strong
●
Profitability
Strong
≈
Cash Flow
Healthy
⚖
Balance Sheet
Strong
💵 Revenue
4.29B
↗ Strong
📈 Net Income
1.30B
↗ Strong
🧮 EPS (Basic)
12.62
↗ Strong
REGENERON PHARMACEUTICALS, INC.
Healthcare • Biotechnology
You Might Also Like